Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17442873 | 0.73 | ALDH1A1 (0.33) | ALDH1A1PKMSLC1A2KMT2AATM | |
| SCHEMBL17442874 | 0.69 | ALDH1A1 (0.46) | ALDH1A1PKMSLC1A2 | |
| SCHEMBL28651718 | 0.68 | LMNA (0.30) | CA12CA1CA9 | |
| SCHEMBL17767818 | 0.68 | ALDH1A1 (0.45) | ALDH1A1PKM | |
| SCHEMBL29843978 | 0.66 | KMT2A (0.31) | KMT2AATM | |
| SCHEMBL23716973 | 0.66 | ALDH1A1 (0.46) | ALDH1A1PKMSLC1A2KMT2AATM | |
| SCHEMBL31259418 | 0.66 | ALDH1A1 (0.46) | ALDH1A1PKMSLC1A2KMT2AATM | |
| SCHEMBL16754920 | 0.66 | ALDH1A1 (0.43) | ALDH1A1PKM | |
| SCHEMBL432176 | 0.65 | ALDH1A1 (0.44) | ALDH1A1PKMSLC1A2KMT2AATM | |
| SCHEMBL202493 | 0.63 | ALDH1A1 (0.43) | ALDH1A1PKMSLC1A2KMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119136797-A | CB1Ligand conjugated compounds and uses thereof | 阿达尔克斯制药有限公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-116635408-A | Reactive conjugates | 德彪药业国际股份公司 | 2023-08-22 | — | — | CN | disclosed |
| EP-2884965-B1 | INTERNAL STRUCTURED SELF ASSEMBLING LIPOSOMES | FROESE AARON (CA) | 2018-08-08 | — | — | EP | disclosed |
| US-9775804-B2 | Internal structured self assembling liposomes | FROESE AARON (CA) | 2017-10-03 | — | — | US | disclosed |
| US-20150231074-A1 | INTERNAL STRUCTURED SELF ASSEMBLING LIPOSOMES | FROESE AARON (CA) | 2015-08-20 | — | — | US | disclosed |
| EP-2884965-A1 | INTERNAL STRUCTURED SELF ASSEMBLING LIPOSOMES | Froese, Aaron (CA) | 2015-06-24 | — | — | EP | disclosed |
| WO-2014026284-A1 | INTERNAL STRUCTURED SELF ASSEMBLING LIPOSOMES | FROESE AARON (CA) | 2014-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150231074-A1 | INTERNAL STRUCTURED SELF ASSEMBLING LIPOSOMES | NASP, PEBP1, SSB | ALDH1A1 4844/4885PKM 2423/4885SLC1A2 4487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.